D01.5, Carcinoma in situ of liver, gallbladder and bile ductsICD-10-CM
No Prior Auth Required
Covered without prior authorization (high confidence)
CGS-J15-L39017, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J15
CGS-J18-L39017, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J18
WPS-J5-L39040, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
A58756, Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
Ask Backwork about documentation requirements, denial risks, or coverage in your state.
NGS-J6-L40334, Erythropoiesis Stimulating Agents
J6
NGS-J6-L40333, Erythropoiesis Stimulating Agents
J6
WPS-J8-L39040, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J8
FIRST_COAST-L33933, Peripheral Nerve Blocks
J9
A57063, Billing and Coding: Diagnostic and Therapeutic Esophagogastroduodenoscopy
J9
FIRST_COAST-L33583, Diagnostic and Therapeutic Esophagogastroduodenoscopy
J9
NOVITAS-JH-L35396, Biomarkers for Oncology
JH
NGS-JK-L40334, Erythropoiesis Stimulating Agents
JK
NGS-JK-L40333, Erythropoiesis Stimulating Agents
JK
A52986, Billing and Coding: Biomarkers for Oncology
JL
NOVITAS-JL-L35396, Biomarkers for Oncology
JL
A58652, Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
A58679, Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
A58734, Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
A58982, Billing and Coding: Erythropoiesis Stimulating Agents
ANTHEM-CG-SURG-78, Locoregional Techniques for Treating Primary and Metastatic Liver Malignancies